Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...

AGMB-447 is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.

The study will enrol 160 patients with IPF who have not previously received treatment.

With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared ...

Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...

Regular glucosamine use is associated with a decreased risk of developing idiopathic pulmonary fibrosis (IPF).

Smoking, obesity, and prolonged corticosteroid use are independent predictors of sarcoidosis recurrence, a recent study found ...

DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider Jeffrey J. Swigris, ...